
Immune system ‘reset’ puts patient with 3 autoimmune diseases into remission: ScienceAlert
In Germany, a 47-year-old woman with three different autoimmune diseases went into complete remission after an experimental treatment that effectively reset her immune system.
The patient previously required daily blood transfusions to manage her condition, two of which affected her blood cells.
She received chimeric antigen receptor (CAR) T-cell therapy, which involves extracting a sample of immune cells, “spiking” them against a specific target and sending them back into the body.
According to a case report published in the journal MedicalThe patient’s symptoms improved within a few weeks of treatment and she no longer requires blood transfusions, even almost a year after treatment.
“The treatment was extremely effective in eliminating all three autoimmune diseases simultaneously,” said Fabian Müller, a hematologist at Erlangen University Hospital in Germany.
“After being ill for over a decade, the patient is now in remission without treatment and is able to return to an almost normal life. This therapy has significantly improved her quality of life.”
The patient’s primary condition was autoimmune hemolytic anemia (AIHA), a rare disease that occurs when the immune system begins to attack red blood cells.
He was later also diagnosed with two related autoimmune diseases: antiphospholipid antibody syndrome, in which antibodies make the blood prone to dangerous clots; and immune thrombocytopenia, where immune cells attack platelets, the small cell fragments that prevent excessive bleeding.
This trio of conditions meant the patient needed blood transfusions every day and had to take blood-thinning medications regularly to prevent clots from forming.
Over the years, she underwent nine different types of treatments to try to improve her health and quality of life, but none worked for very long.
“The speed and depth of the response has been remarkable.” – hematologist Fabian Müller
The case study details the woman’s clinical progress with CAR T cell therapy, which is showing increasing promise in the treatment of a variety of cancers.
Rather than using chemicals or radiation to kill cancer cells, this treatment teaches the body’s immune system to hunt down a specific target more effectively.
CAR T cells have also been used previously to treat this type of anemia.
A study published in January reported that 11 people whose AIHA had resisted several previous treatments went into complete remission after a single infusion. Two relapsed after about eight months, but responded to a second, differently targeted treatment.
The team behind this work also previously developed CAR-T cell therapy to combat other autoimmune diseases, including lupus, myositis and systemic sclerosis, with patients going into remission.
In this case, the problems all seemed to stem from B cells, which produce antibodies as part of an adaptive immune response.
However, the patient’s B cells had gone haywire and were directing the rest of her immune system to attack red blood cells, platelets and healthy tissue.
So, the researchers isolated these T cells and “supercharged” them to attack a protein present on the surface of B cells, called CD19. The T cells were then injected back into the patient’s bloodstream, where they could go to work killing off her unwanted B cells.

And sure enough, his health began to improve almost immediately. Seven days after the single CAR T cell infusion, she no longer needed blood transfusions.
“After discharge on day 10, the patient experienced a rapid and remarkable increase in physical strength and was able to carry out normal daily activities,” the researchers write in their case report.
By day 25, biomarkers indicated she had entered complete remission.
His hemoglobin level returned to normal after being significantly reduced – this protein is found in red blood cells, so its increase indicates that these cells were no longer destroyed.
Her platelet count stabilized and the antibodies that trigger blood clots also dropped and eventually became undetectable.

“After more than 10 years of illness, the patient’s blood count normalized in just a few weeks,” Müller said.
“The speed and depth of the response has been remarkable.”
After 322 days, the patient’s B cells began to reappear, but, more importantly, almost all of them were “naïve,” meaning they did not retain immune memory and therefore did not attack healthy cells.
Around the same time, the patient was able to stop taking the medications to prevent blood clots, with no signs of new clots forming. She did not experience any of the serious immune reactions that CAR T cell therapy can cause, such as cytokine release syndrome or nerve toxicity.
Her liver enzymes were slightly elevated and her platelet count dropped, which could be a lingering effect of her many previous treatments, the team said.
Hematologist Cristina Pascual Izquierdo, who was not involved in the work, cautioned that the report was not definitive proof but said “the clinical relevance is notable” as an early sign.
“The limitations of this study are those inherent in the publication of a single clinical case, with a limited follow-up of 11 months,” Pascual Izquierdo told Science Media Center Spain.
“This study provides highly suggestive preliminary evidence that anti-CD19 CAR-T therapy can induce deep and simultaneous remissions in B cell-mediated autoimmune diseases, even in extremely refractory cases.”
So while a single case cannot confirm that the therapy will work for all patients, these and other results provide hope.
“We believe that early use of CAR-T therapy in patients with severe autoimmune disease could help prevent complications related to years of ineffective treatments,” Müller said.
A review published in June in The hematologist describes CAR-T results reported thus far for autoimmune blood diseases, including this case.
Related: Two people with serious autoimmune disease in remission after immune ‘reset’
Of course, effective treatment also relies on a correct diagnosis, and research suggests it may take longer for women with an autoimmune disease.
A new survey of 6,607 people with autoimmune diseases, published in eMedicineClinicalfound that the most common wait for a diagnosis was less than three months – for men.
Women most often waited one to two hours yearsand 43 percent said their symptoms had at some point been attributed to a psychiatric cause.
“If we can intervene earlier,” Müller said in April, “we may be able to stop the disease process, prevent organ damage and restore life to patients.”
The research was published in the journal Medical.
This article was fact-checked by Rebecca Dyer and edited by Rebecca Dyer. Although we are proud of our process, we are only human. If you spot an error, please let us know.
Gn Health
))>